9:25 am Chairperson’s Opening Remarks

  • Robert Lutz Chief Scientific Officer, Iksuda Therapeutics

Improving Potency & Efficacy Through Design of Your ADC

9:30 am Strategies to Maximize the Effectiveness of Belantamab Mafodotin


  • Leveraging antibody effector functions in combination with cytotoxic payloads
  • Discussing manipulation of cell surface levels of target to maximize potency
  • Examining the effect of DAR on efficacy

10:00 am Design Considerations for an Immunology Antibody Drug Conjugate (iADC)

  • Adrian Hobson Senior Research Fellow, Drug Discovery Science & Technology Antibody-Drug Conjugates, AbbVie


  • Outlining identification of the antibody target and parameters for selection and parameters of the optimal antibody
  • Discussing considerations when choosing the payload MoA pairing for the antibody target
  • Modifying of the ADC to both maximize the therapeutic index and afford the optimal physiochemical properties

10:30 am
Morning Break & Networking

Analyzing Approaches to Limit On-Target / Off-Tumor Toxicities

11:00 am A Critical Appraisal of Target Mediated & On-Target/Off-Tumor Toxicities of ADCs


  • Understanding the critical importance of target expression and biology in maximizing the therapeutic index
  • Discussing the challenges of predicting on target toxicities based on target expression on normal tissues
  • Outlining the importance of the antibody quality, payload potency, linker and conjugation on target medicated toxicities

11:30 am Designing Site-Specific ADCs to Maximize Target-Mediated Payload Delivery


  • Outlining HT identification of bioconjugation site from ADC libraries
  • Discovering glycosylated variants amenable to bTGase conjugation
  • Discussing characterization of thermal and metabolic stabilities of site-specific ADCs to guide construct design for maximizing target-dependent delivery

12:00 pm pHLAs as Novel Targets & Therapeutic Index Guided ADC Development


  • pHLAs: an emerging class of ADC targets
  • Therapeutic Index based stage gate decisions to guide ADC development
  • Immunogenic cell death of payloads to increase DOR and PFS of ADCs

12:30 pm
Lunch & Networking

Harnessing Bioinformatics for Improved Target Selection

1:30 pm Quantitative Proteomics Approaches for ADC Target Characterization


  • Discussing DIA-MS peptide level quantification for epitope and isoform precision
  • Explore how to quantify cell surface protein dynamics using pulsed SILAC labeling
  • Examine the profiling of protein drug interactions (PDIs) Using IP-MS

2:00 pm A Novel B7H3 ADC With Strong Bystander Effect Demonstrates Superior Tumor-Inhibition Activity

  • Jin-Chen Yu Senior Vice President, Preclinical Research, Bio-Thera Solutions


  • Outlining B7H3 as a target and our novel ADC technique
  • Discussing in vitro characterization and in vivo anti-tumor activity of BAT8009
  • Reviewing Preclinical PK and GLP toxicity study and clinical plan/progress

2:30 pm Chairperson’s Closing Remarks

2:35 pm End of Conference